US-based medical technology company Novanta has announced a major business deal. The company plans to buy Riverpoint Medical for $1.2 billion in cash. The agreement also includes an extra payment of $250 million if Riverpoint reaches certain business goals in early 2027. Because of this, the total value of the deal may rise to $1.45 billion.
The news has drawn attention across the medical technology industry. Experts see this move as one of the biggest deals in Novanta’s history. The company hopes this purchase will help it grow faster in the global healthcare market.
Novanta shared the announcement through an official statement. The company said the deal will strengthen its medical business and open new opportunities in surgical technology.
What Novanta Does
Novanta is a US-based technology company. It creates products and systems for the medical, life science, and industrial sectors. The company works with equipment makers across the world. Its technology supports medical tools, robotics, laser systems, and advanced machines.
Over the years, Novanta has built a strong position in the healthcare sector. The company focuses on high-quality technology that helps doctors and hospitals improve patient care. Its products support modern surgeries and medical treatments.
Healthcare has become the biggest growth area for Novanta. The company now wants to expand even more through this latest purchase.
Riverpoint Medical Has Strong Surgical Business
Riverpoint Medical is based in Portland, Oregon. The company develops and manufactures medical devices used during surgeries and medical procedures. It is well known for products such as surgical sutures, mesh products, and advanced wound closure systems.
Hospitals and healthcare providers use Riverpoint products in many types of surgeries. The company has built a solid name in the medical device market because of its focus on quality and innovation.
Riverpoint also has strong customer relationships in the healthcare sector. This makes the company an attractive choice for buyers who want a larger presence in surgical technology.
Full Value of the Deal May Reach $1.45 Billion
Novanta will first pay $1.2 billion in cash to complete the acquisition. On top of that, Riverpoint may receive another $250 million later. This payment depends on business targets that the company must achieve by early 2027.
Because of this structure, many reports mention two different numbers. Some headlines focus only on the $1.2 billion upfront payment. Others mention the possible total value of $1.45 billion.
The deal is expected to close during the third quarter of 2026. However, both companies still need approval from regulators before final completion.
Novanta Wants Bigger Role in Surgery Market
One of the main reasons behind this acquisition is the fast growth in minimally invasive surgery. This type of surgery uses smaller cuts and advanced tools. Patients often recover faster and face less pain after treatment.
Medical companies across the world now invest heavily in this area. Novanta believes Riverpoint can help it become a bigger player in this market.
After the acquisition, Novanta expects stronger sales from medical consumables. Consumables include products that doctors and hospitals use regularly and replace after use. These products usually provide stable revenue because hospitals need them every day.
The company expects recurring medical consumable revenue to rise to nearly $300 million each year after the deal.
Medical Segment Will Become Larger
Novanta already earns a large share of revenue from healthcare products. After the Riverpoint acquisition, the medical business may account for around 60 percent of total company revenue.
This change shows how important healthcare has become for Novanta’s future plans. The company sees strong long-term demand in medical technology and surgical equipment.
Executives believe the combination of both companies will create better opportunities with existing customers. Many hospitals and medical firms already work with both businesses. Novanta hopes this will lead to stronger customer relationships and larger contracts.
Company Expects Strong Financial Benefits
Novanta believes the acquisition will also improve profits over time. The company expects more than $80 million in combined profit and cash flow benefits during the first five years after the deal closes.
These benefits may come from better production systems, stronger supply chains, and improved sales operations. Large companies often save money after acquisitions because they can combine teams, factories, and business operations.
Investors usually pay close attention to these expected savings. Strong financial gains can help justify the high cost of large acquisitions.
Funding Plan for the Acquisition
Novanta recently completed a $300 million private placement to support the purchase. A private placement allows companies to raise money from selected investors instead of public markets.
The company also secured additional borrowing power through changes to its credit agreements. This gives Novanta enough financial support to complete the acquisition.
Large acquisitions often require a mix of cash, loans, and investor support. Novanta appears confident that its financial position can support the deal without major problems.
Arlington Capital Partners Will Exit Investment
Riverpoint Medical is currently backed by Arlington Capital Partners. The investment firm bought a majority stake in Riverpoint in 2019.
Private investment firms often buy companies, help them grow, and later sell them for a profit. This deal now gives Arlington an exit opportunity after several years of ownership.
During Arlington’s ownership period, Riverpoint expanded its business and strengthened its product portfolio. These improvements likely increased the company’s value before the sale.
Medical Technology Industry Sees More Consolidation
The Novanta-Riverpoint deal also reflects a larger trend in the healthcare industry. Medical technology companies across the world continue to merge and acquire smaller firms.
Many businesses want stronger positions in high-growth sectors such as surgical devices, robotics, and minimally invasive treatments. Companies also seek stable revenue from consumable medical products.
Industry experts believe this trend may continue in coming years as healthcare demand rises worldwide. Aging populations and new medical technologies continue to create fresh business opportunities.
For Novanta, this acquisition could become a major step in its long-term growth strategy. The company hopes Riverpoint will strengthen its market position and improve future earnings.
If regulators approve the transaction as expected, the deal may officially close in the third quarter of 2026. After that, Novanta will begin the process of combining Riverpoint into its medical business operations.
Also Read – How to Get a Job at OpenAI in 2026: Complete Guide